Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 293, Issue 1, 2007, Pages

  Simonsen, Lotte ^a   Pilgaard, Sofie ^a   Orskov, Cathrine ^a   Rosenkilde, Mette M ^a   Hartmann, Bolette ^a,c   Holst, Jens J ^a   Deacon, Carolyn F ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Sanos Bioscience   (Denmark)

Author keywords

Glucagon like peptide 1; Glucagon like peptide 1 receptor; Glucagon like peptide 2; Glucagon like peptide 2 receptor; Intestinotrophic

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; HEMOGLOBIN A1C; NN 7201; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE GROWTH; CONTROLLED STUDY; DRUG INHIBITION; HEMOGLOBIN DETERMINATION; HORMONAL REGULATION; INSULIN LIKE ACTIVITY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; SMALL INTESTINE ABSORPTION; SMALL INTESTINE MUCOSA; UPREGULATION;

ANIMALS; ANTIGENS, CD26; BODY WEIGHT; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; EATING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTESTINE, SMALL; MALE; PEPTIDES; PROTEASE INHIBITORS; RATS; RECEPTORS, GLUCAGON; TRANSFECTION; VENOMS; XANTHINES;

EID: 34547133061     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00453.2006     Document Type: Article

References (39)

1. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25: 869-875, 2002.
2. Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52: 252-259, 2003.
3. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 81: 1005-1012, 2003.
4. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996.
5. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, Schmidt M, Holst JJ, Hartmann B, Sangild PT. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 279: G1249-G1256, 2000.
6. Christel CM, Denardo DF. Release of exendin-4 is controlled by mechanical action in Gila monsters, Heloderma suspectum. Comp Biochem Physiol A 143: 85-88, 2006.
7. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53: 2181-2189, 2004.
8. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
9. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172: 355-362, 2002.
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092-1100, 2005.
11. Kim D, Macconell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. In press.
12. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93: 7911-7916, 1996.
13. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA. Reduced increments in total glucagon like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in plasma after a single dose of the dipetidyl peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects (Abstract). Diabetologia 42, Suppl. 1: A284, 2004.
14. Faidley TD, Leiting B, Pryor KD, Lyons K, Hickey GJ, Thompson DR. Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. Exp Biol Med (Maywood) 231: 1373-1378, 2006.
15. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25: 781-792, 2001.
16. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 83: 1533-1540, 1989.
17. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol 246: 29-31, 1988.
18. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278: E1010-E1018, 2000.
19. Hansen L, Hartmann B, Mineo H, Holst JJ. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118: 11-18, 2004.
20. Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85: 2884-2888, 2000.
21. Hartmann B, Thulesen J, Hare KJ, Kissow H, Orskov C, Poulsen SS, Holst JJ. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 105: 173-179, 2002.
22. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS, Holst JJ. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141: 4013-4020, 2000.
23. Hiles R, Carpenter T, Serota D, Schafer K, Ross P, Nelson D, Rebelatto M. Exenatide does not cause pancreatic tumors or malignancies in rats and mice following a 2-year period of exposure (Abstract). Diabetes 53, Suppl 2: A380, 2004.
24. Larsen PJ, Vrang N, Tang-Christensen M, Jensen PB, Hay-Schmidt A, Romer J, Bjerre-Knudsen L, Kristensen P. Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides. Eur J Pharmacol 440: 159-172, 2002.
25. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97: 6874-6879, 2000.
26. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167-194, 2003.
27. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119: 1467-1475, 1986.
28. Orskov C, Poulsen SS. Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 40: 1292-1296, 1991.
29. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
30. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38: 423-428, 2006.
31. Raun K, von VP, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV Inhibitor, vildagliptin, does not. Diabetes 56: 8-15, 2007.
32. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133: 233-240, 1993.
33. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274: 956-961, 1999.
34. Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman ER, Jacobs DO, Zinner MJ, Ashley SW, Whang EE. Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J Surg Res 91: 77-82, 2000.
35. Thulesen J. Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. Curr Protein Pept Sci 5: 51-65, 2004.
36. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137-1143, 1999.
37. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 272: E77-E84, 1997.
38. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 145: 1349-1355, 2004.
39. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673, 1993.